Israel - Inggeris - Ministry of Health

organon pharma israel ltd., israel - carbidopa as monohydrate; levodopa - tablets controlled release - levodopa 200 mg; carbidopa as monohydrate 50 mg - levodopa and decarboxylase inhibitor - idiopathic parkinson's disease. postencephalitic parkinsonism. symptomatic parkinsonism. to reduce "off" time in patients previously treated with levodopa/decarboxylase inhibitor preparations, or with levodopa alone, who have had motor fluctuations characterized by end-of-dose deterioration ("wearing-off" phenomenon), peak dose dyskinesias, akinesia, or similar evidence of short-duration motor disturbances.

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - amantadine hydrochloride, quantity: 100 mg - capsule, soft - excipient ingredients: titanium dioxide; glycerol; lecithin; sodium propyl hydroxybenzoate; yellow beeswax; partially hydrogenated soya oil; iron oxide red; gelatin; sodium ethyl hydroxybenzoate; hydrogenated soya oil; rape seed oil; maize starch; sorbitol; mannitol; ethyl acetate; butan-1-ol; shellac; industrial methylated spirit - parkinson's disease: idiopathic parkinson's disease; post encephalitic parkinsonism; symptomatic parkinsonism (e.g. following cns injury from carbon monoxide poisoning); arteriosclerotic parkinsonism; drug-induced extrapyramidal reactions. symmetrel can be given alone for initial therapy or combined with anticholinergic drugs or l-dopa (see "dosage and administration"). note: symmetrel is not indicated for the treatment of tardive dyskinesia. type a virus influenza: prophylaxis of respiratory tract illness caused by influenza type a. prophylaxis in non-immunized individuals (including children) for whom influenza may have serious consequences (e.g. persons with chronic respiratory disease of diabetes mellitus).

Kesatuan Eropah - Inggeris - EMA (European Medicines Agency)

orion corporation - levodopa, carbidopa, entacapone - parkinson disease - anti-parkinson drugs - corbilta is indicated for the treatment of adult patients with parkinson’s disease and end-of-dose motor fluctuations not stabilised on levodopa/dopa decarboxylase (ddc) inhibitor treatment.

Kesatuan Eropah - Inggeris - EMA (European Medicines Agency)

orion corporation - levodopa, carbidopa, entacapone - parkinson disease - anti-parkinson drugs - stalevo is indicated for the treatment of adult patients with parkinson's disease and end-of-dose motor fluctuations not stabilised on levodopa / dopa-decarboxylase (ddc)-inhibitor treatment.

Amerika Syarikat - Inggeris - NLM (National Library of Medicine)

synedgen, inc. - poly(n-acetyl, n-arginyl)glucosamine (50000-80000 mw) (unii: ua7my2jy0e) (poly(n-acetyl, n-arginyl)glucosamine (50000-80000 mw) - unii:ua7my2jy0e) - poly(n-acetyl, n-arginyl)glucosamine (50000-80000 mw) 1 g in 1 g - derived from chitin obtained from arctic shrimp shells, synoplex® has an approximate molecular weight of 20 to 100 kda. each gram of synoplex® contains 1 gram of poly (acetyl, arginyl) glucosamine. synoplex® is supplied as a dry soluble powder, that is rehydrated with sterile water prior to use. synoplex® acts on the bacterial membrane causing aggregation of bacteria and pore formation leading to reduction of viable bacteria and prevention of biofilm formation.

Kesatuan Eropah - Inggeris - EMA (European Medicines Agency)

bial - portela cª, s.a. - opicapone - parkinson disease - anti-parkinson drugs - ongentys is indicated as adjunctive therapy to preparations of levodopa/ dopa decarboxylase inhibitors (ddci) in adult patients with parkinson’s disease and end-of-dose motor fluctuations who cannot be stabilised on those combinations.ongentys is indicated as adjunctive therapy to preparations of levodopa/ dopa decarboxylase inhibitors (ddci) in adult patients with parkinson’s disease and end-of-dose motor fluctuations who cannot be stabilised on those combinations.

Kesatuan Eropah - Inggeris - EMA (European Medicines Agency)

bial portela & companhia s.a. - opicapone - parkinson disease - anti-parkinson drugs - ontilyv is indicated as adjunctive therapy to preparations of levodopa/ dopa decarboxylase inhibitors (ddci) in adult patients with parkinson’s disease and end-of-dose motor fluctuations who cannot be stabilised on those combinations.

Kesatuan Eropah - Inggeris - EMA (European Medicines Agency)

orion corporation - entacapone - parkinson disease - anti-parkinson drugs - entacapone is indicated as an adjunct to standard preparations of levodopa / benserazide or levodopa / carbidopa for use in adult patients with parkinson's disease and end-of-dose motor fluctuations, who cannot be stabilised on those combinations.

Kesatuan Eropah - Inggeris - EMA (European Medicines Agency)

orion corporation - entacapone - parkinson disease - anti-parkinson drugs - entacapone is indicated as an adjunct to standard preparations of levodopa / benserazide or levodopa / carbidopa for use in patients with parkinson's disease and end-of-dose motor fluctuations, who cannot be stabilised on those combinations.

Kesatuan Eropah - Inggeris - EMA (European Medicines Agency)

orion corporation - entacapone - parkinson disease - anti-parkinson drugs - entacapone is indicated as an adjunct to standard preparations of levodopa / benserazide or levodopa / carbidopa for use in adult patients with parkinson's disease and end-of-dose motor fluctuations, who cannot be stabilised on those combinations.